secwatch / observer

8-K filed December 7, 2021, 6:59 PM ET ticker CELZ CIK 0001187953

other material confidence high sentiment positive materiality 0.75

Creative Medical Technology Holdings prices $16M public offering, uplists to Nasdaq, appoints new directors

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

Priced 3.875M shares and warrants at $4.13 per combined unit; gross proceeds ~$16M.
Common stock begins trading on Nasdaq Capital Market under ticker CELZ as of Dec 3, 2021.
Thomas Ichim and Amit Patel resigned as directors; Michael Finger, Susan Snow, Bruce Urdang appointed.
Proceeds to redeem $5.1M in senior notes, repurchase ~$195k of Series A preferred from CEO, fund clinical trials.
Underwriter Roth Capital granted 45-day option for up to 581,250 additional shares/warrants.

item 1.01 item 3.01 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Michael H. Finger

Director

CELZ · CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

Effective: 2021-12-02
Filed: December 7, 2021, 6:59 PM ET

Michael H. Finger, Susan Snow and Bruce S. Urdang were appointed to serve as directors of the Company.

Departed

Thomas Ichim

Director

CELZ · CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

Effective: 2021-12-02
Filed: December 7, 2021, 6:59 PM ET

Drs. Thomas Ichim and Amit Patel resigned as directors of the Company;

Appointed

Bruce S. Urdang

Director

CELZ · CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

Effective: 2021-12-02
Filed: December 7, 2021, 6:59 PM ET

Michael H. Finger, Susan Snow and Bruce S. Urdang were appointed to serve as directors of the Company.

Departed

Amit Patel

Director

CELZ · CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

Effective: 2021-12-02
Filed: December 7, 2021, 6:59 PM ET

Drs. Thomas Ichim and Amit Patel resigned as directors of the Company;

Appointed

Susan Snow

Director

CELZ · CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

Effective: 2021-12-02
Filed: December 7, 2021, 6:59 PM ET

Michael H. Finger, Susan Snow and Bruce S. Urdang were appointed to serve as directors of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael H. Finger was appointed as Director at CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC..

Action: appointed
Role: Director

Exact text from the filing

Michael H. Finger, Susan Snow and Bruce S. Urdang were appointed to serve as directors of the Company.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Thomas Ichim resigned as Director at CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC..

Action: resigned
Role: Director

Exact text from the filing

Drs. Thomas Ichim and Amit Patel resigned as directors of the Company;

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Bruce S. Urdang was appointed as Director at CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC..

Action: appointed
Role: Director

Exact text from the filing

Michael H. Finger, Susan Snow and Bruce S. Urdang were appointed to serve as directors of the Company.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Amit Patel resigned as Director at CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC..

Action: resigned
Role: Director

Exact text from the filing

Drs. Thomas Ichim and Amit Patel resigned as directors of the Company;

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Susan Snow was appointed as Director at CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC..

Action: appointed
Role: Director

Exact text from the filing

Michael H. Finger, Susan Snow and Bruce S. Urdang were appointed to serve as directors of the Company.

View on SEC.gov

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001477932-21-009015

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.